Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stinchcombe

Showing results (531-540 of 575) with videos related to

Pageof 58
Sort By:
Immunotherapy|April 21, 2021
Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO)Jacob M Sands, Sumithra J Mandrekar, David Kozono, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2019
Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508Suresh S Ramalingam, Suzanne E Dahlberg, Chandra P Belani, et al.
JAMA Oncology|July 25, 2024
Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II Nonrandomized Controlled TrialHelen J Ross, David Kozono, Xiaofei F Wang, et al.
The New England Journal of Medicine|February 13, 2023
Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung CancerNasser Altorki, Xiaofei Wang, David Kozono, et al.
Clinical Lung Cancer|February 15, 2021
Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400GTaofeek K Owonikoko, Mary W Redman, Lauren A Byers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2017
Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance)Martin J Edelman, Xiaofei Wang, Lydia Hodgson, et al.
Lung Cancer (Amsterdam, Netherlands)|September 17, 2014
Alterations of LKB1 and KRAS and risk of brain metastasis: comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinomaNi Zhao, Matthew D Wilkerson, Usman Shah, et al.
The Annals of Thoracic Surgery|February 5, 2024
The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung CancerElizabeth G Dunne, Cameron N Fick, James M Isbell, et al.
Accident; Analysis and Prevention|November 28, 2018
Self-reported violations, errors and lapses for older drivers: Measuring the change in frequency of aberrant driving behaviours across five time-pointsSjaan Koppel, Amanda N Stephens, Michel Bédard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2017
Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group StudiesThomas E Stinchcombe, Ying Zhang, Everett E Vokes, et al.
Pageof 58

Showing results (531-540 of 575) with videos related to

Sort By:
Pageof 58
Immunotherapy|April 21, 2021
Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO)Jacob M Sands, Sumithra J Mandrekar, David Kozono, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2019
Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508Suresh S Ramalingam, Suzanne E Dahlberg, Chandra P Belani, et al.
JAMA Oncology|July 25, 2024
Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II Nonrandomized Controlled TrialHelen J Ross, David Kozono, Xiaofei F Wang, et al.
The New England Journal of Medicine|February 13, 2023
Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung CancerNasser Altorki, Xiaofei Wang, David Kozono, et al.
Clinical Lung Cancer|February 15, 2021
Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400GTaofeek K Owonikoko, Mary W Redman, Lauren A Byers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2017
Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance)Martin J Edelman, Xiaofei Wang, Lydia Hodgson, et al.
Lung Cancer (Amsterdam, Netherlands)|September 17, 2014
Alterations of LKB1 and KRAS and risk of brain metastasis: comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinomaNi Zhao, Matthew D Wilkerson, Usman Shah, et al.
The Annals of Thoracic Surgery|February 5, 2024
The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung CancerElizabeth G Dunne, Cameron N Fick, James M Isbell, et al.
Accident; Analysis and Prevention|November 28, 2018
Self-reported violations, errors and lapses for older drivers: Measuring the change in frequency of aberrant driving behaviours across five time-pointsSjaan Koppel, Amanda N Stephens, Michel Bédard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2017
Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group StudiesThomas E Stinchcombe, Ying Zhang, Everett E Vokes, et al.
Pageof 58